Introduction
Galera Therapeutics (GRTX) is a relatively small biotech company that has an attractive drug asset with breakthrough and fast track designation. Furthermore, the company is backed by very big and prestigious biotech venture capital funds, such as Sofinnova Venture Partners, Novartis Bioventures, or Novo Holdings. Despite all this, the company is very reasonably priced at the moment, which caught our interest. Therefore, we dug further into the potential of GC4419 for the treatment of oral mucositis for patients with solid tumors.
Head and neck cancers
“Head and neck cancers” ((HNC)) is the term used